Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: Effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size

Neurobiology of Aging

Volumn 35, Issue 4, 2014, Pages 808-818

  Yu, Peng ^a   Sun, Jia ^a,b   Wolz, Robin ^c,d   Stephenson, Diane ^e   Brewer, James ^f   Fox, Nick C ^g   Cole, Patricia E ^a   Jack, Clifford R ^h   Hill, Derek L G ^c,g   Schwarz, Adam J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c IXICO PLC   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e CRITICAL PATH INSTITUTE   (United States)

^f UNIVERSITY OF SAN DIEGO   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h MAYO CLINIC   (United States)

Author keywords

Biomarker; Clinical trials; Enrichment; Hippocampal volume; Hippocampus; Inclusion criterion; MRI; Structural MRI

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ALGORITHM; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; BRAIN SIZE; CLINICAL DEMENTIA RATING SUM OF BOXES; COHORT ANALYSIS; CONTROLLED STUDY; COST; CUT POINT; FEMALE; FREESURFER; HIPPOCAMPUS; HIPPOCAMPUS MULTI ATLAS PROPAGATION AND SEGMENTATION; HUMAN; LEARNING EMBEDDINGS ATLAS PROPAGATION; MALE; MATHEMATICAL PARAMETERS; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROQUANT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PRIORITY JOURNAL; SAMPLE SIZE; SCORING SYSTEM; SCREENING TEST; TEST RETEST RELIABILITY; VERY ELDERLY;

BIOMARKER; CLINICAL TRIALS; ENRICHMENT; HIPPOCAMPAL VOLUME; HIPPOCAMPUS; INCLUSION CRITERION; MRI; STRUCTURAL MRI;

AGED; AGED, 80 AND OVER; ALGORITHMS; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; PATIENT SELECTION; SAMPLE SIZE;

EID: 84891371826     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.09.039     Document Type: Article

References (32)

1. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
2. Barnes J., Bartlett J.W., Fox N.C., Schott J.M. Targeted recruitment using cerebrospinal fluid biomarkers: implications for Alzheimer's disease therapeutic trials. J.Alzheimers Dis. 2013, 34:431-437.
3. Bartlett J.W., Frost C., Mattsson N., Skillback T., Blennow K., Zetterberg H., Schott J.M. Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. Biomark. Med. 2012, 6:391-400.
4. Boccardi M., Ganzola R., Bocchetta M., Pievani M., Redolfi A., Bartzokis G., Camicioli R., Csernansky J.G., de Leon M.J., deToledo-Morrell L., Killiany R.J., Lehericy S., Pantel J., Pruessner J.C., Soininen H., Watson C., Duchesne S., Jack C.R., Frisoni G.B. Survey of protocols for the manual segmentation of the hippocampus: preparatory steps towards a joint EADC-ADNI harmonized protocol. J.Alzheimers Dis. 2011, 26(suppl 3):61-75.
5. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta. Neuropathol. 1991, 82:239-259.
6. Brewer J.B. Fully-automated volumetric MRI with normative ranges: translation to clinical practice. Behav. Neurol. 2009, 21:21-28.
7. Desikan R.S., Cabral H.J., Hess C.P., Dillon W.P., Glastonbury C.M., Weiner M.W., Schmansky N.J., Greve D.N., Salat D.H., Buckner R.L., Fischl B. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 2009, 132:2048-2057.
8. Devanand D.P., Pradhaban G., Liu X., Khandji A., De Santi S., Segal S., Rusinek H., Pelton G.H., Honig L.S., Mayeux R., Stern Y., Tabert M.H., de Leon M.J. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007, 68:828-836.
9. Fischl B. FreeSurfer. Neuroimage 2012, 62:774-781.
10. Fischl B., Salat D.H., Busa E., Albert M., Dieterich M., Haselgrove C., van der Kouwe A., Killiany R., Kennedy D., Klaveness S., Montillo A., Makris N., Rosen B., Dale A.M. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355.
11. Henneman W.J., Sluimer J.D., Barnes J., van der Flier W.M., Sluimer I.C., Fox N.C., Scheltens P., Vrenken H., Barkhof F. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 2009, 72:999-1007.
12. Hill, D.L.G., Schwarz, A.J., Isaac, M., Pani, L., Vamvakas, S., Hemmings, R., Carrillo, M.C., Yu, P., Sun, J., Beckett, L., Boccardi, M., Brewer, J., Brumfield, M., Cole, P.E., Fox, N., Frisoni, G.B., Jack, C., Kelleher, T., Luo, F., Novak, G., Maguire, P., Meibach, R., Patterson, P., Bain, L., Sampaio, C., Soares, H., Suhy, J., Wang, H., Wolz, R., Stephenson, D., 2013. CAMD/EMA biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. Alzheimer's & Dementia (in press).
13. Jack C.R., Barkhof F., Bernstein M.A., Cantillon M., Cole P.E., Decarli C., Dubois B., Duchesne S., Fox N.C., Frisoni G.B., Hampel H., Hill D.L., Johnson K., Mangin J.F., Scheltens P., Schwarz A.J., Sperling R., Suhy J., Thompson P.M., Weiner M., Foster N.L. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement. 2011, 7:474-485.
14. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
15. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
16. Jack C.R., Knopman D.S., Weigand S.D., Wiste H.J., Vemuri P., Lowe V., Kantarci K., Gunter J.L., Senjem M.L., Ivnik R.J., Roberts R.O., Rocca W.A., Boeve B.F., Petersen R.C. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann. Neurol. 2012, 71:765-775.
17. Jack C.R., Petersen R.C., Xu Y.C., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Waring S.C., Tangalos E.G., Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999, 52:1397-1403.
18. Jack C.R., Shiung M.M., Weigand S.D., O'Brien P.C., Gunter J.L., Boeve B.F., Knopman D.S., Smith G.E., Ivnik R.J., Tangalos E.G., Petersen R.C. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005, 65:1227-1231.
19. Jedynak B.M., Lang A., Liu B., Katz E., Zhang Y., Wyman B.T., Raunig D., Jedynak C.P., Caffo B., Prince J.L. Acomputational neurodegenerative disease progression score: method and results with the Alzheimer's disease neuroimaging initiative cohort. Neuroimage 2012, 63:1478-1486.
20. Jicha G.A., Parisi J.E., Dickson D.W., Johnson K., Cha R., Ivnik R.J., Tangalos E.G., Boeve B.F., Knopman D.S., Braak H., Petersen R.C. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch. Neurol. 2006, 63:674-681.
21. Killiany R.J., Hyman B.T., Gomez-Isla T., Moss M.B., Kikinis R., Jolesz F., Tanzi R., Jones K., Albert M.S. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 2002, 58:1188-1196.
22. Leung K.K., Barnes J., Ridgway G.R., Bartlett J.W., Clarkson M.J., Macdonald K., Schuff N., Fox N.C., Ourselin S. Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage 2010, 51:1345-1359.
23. Lorenzi M., Donohue M., Paternico D., Scarpazza C., Ostrowitzki S., Blin O., Irving E., Frisoni G.B. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiol. Aging 2010, 31:1443-1451.
24. Mitchell A.J., Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia: meta-analysis of 41 robust inception cohort studies. Acta Psychiatr. Scand. 2009, 119:252-265.
25. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J.Intern. Med. 2004, 256:183-194.
26. Petersen R.C. Mild Cognitive impairment. New England Journal of Medicine 2011, 364:2227-2234.
27. Petersen R.C., Parisi J.E., Dickson D.W., Johnson K.A., Knopman D.S., Boeve B.F., Jicha G.A., Ivnik R.J., Smith G.E., Tangalos E.G., Braak H., Kokmen E. Neuropathologic features of amnestic mild cognitive impairment. Arch. Neurol. 2006, 63:665-672.
28. Vos S., van Rossum I., Burns L., Knol D., Scheltens P., Soininen H., Wahlund L.O., Hampel H., Tsolaki M., Minthon L., Handels R., L'Italien G., van der Flier W., Aalten P., Teunissen C., Barkhof F., Blennow K., Wolz R., Rueckert D., Verhey F., Visser P.J. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol. Aging 2012, 33:2272-2281.
29. Wolz R., Aljabar P., Hajnal J.V., Hammers A., Rueckert D. LEAP: learning embeddings for atlas propagation. Neuroimage 2010, 49:1316-1325.
30. Wolz, R., Schwarz, A.J., Yu, P., Cole, P.E., Rueckert, D., Jack, C.R., Raunig, D., Hill, D.L., 2012. Robustness of automated hippocampal volumetry across MR fieldstrengths and same-session repeat scans. Alzheimer's & Dementia (in press).
31. Wyman B.T., Harvey D.J., Crawford K., Bernstein M.A., Carmichael O., Cole P.E., Crane P.K., Decarli C., Fox N.C., Gunter J.L., Hill D., Killiany R.J., Pachai C., Schwarz A.J., Schuff N., Senjem M.L., Suhy J., Thompson P.M., Weiner M., Jack C.R. Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimers Dement 2013, 9:332-337.
32. Yu P., Dean R.A., Hall S.D., Qi Y., Sethuraman G., Willis B.A., Siemers E.R., Martenyi F., Tauscher J.T., Schwarz A.J. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. J.Alzheimers Dis. 2012, 32:373-385.